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Despite the importance of cardiovascular disease in dialysis
patients, the frequency of atrial fibrillation in incident dialysis
patients has not been determined. We analyzed the
prevalence of atrial fibrillation in patients starting dialysis
over a 4-year period, its occurrence over the course of dialysis,
and its influence on ischemic stroke and mortality. Factors
predisposing to atrial fibrillation were noted, as was the
influence of arrhythmia on mortality and presentation of
ischemic stroke. Of the 256 patients studied, 31 had atrial
fibrillation at the start of dialysis. Increased age, larger left
atrium, and female gender were independently related to the
presence of atrial fibrillation at dialysis inception. Of the 225
patients who were in sinus rhythm at the start of dialysis, 28
developed atrial fibrillation during a mean follow-up time of
2 years. The presence of valvular calcifications, bundle branch
block, previous ischemic stroke, lower ejection fraction,
higher pulse pressure, and lower hemoglobin concentration
were predictors of the clinical evolution of atrial fibrillation.
Overall, atrial fibrillation increased mortality risk 1.72-fold
and ischemic stroke risk 9.8-fold. Therefore, it appears
that atrial fibrillation is quite prevalent and its presence
is associated with significant risk.
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The importance of cardiovascular disease in dialysis patients
with chronic renal insufficiency is currently well established.
Cardiovascular disease constitutes the principal cause of
death in this population group.1,2 Atrial fibrillation (AF) is
the sustained arrhythmia most frequently encountered in
routine clinical practice in the general population, but it also
represents an important social and health-care problem.3,4
Despite this, AF in dialysis patients has only recently
merited some attention in the medical literature.5,6 Over the
past few years, there have been studies that have evaluated
this arrhythmia in this patient population, and the findings
indicate that it is a very frequent disease with a prevalence
that varies between 11 and 27%,7–9 and with an annual
incidence of between 3.1 and 4.1 in patients on dialysis
treatment.10,11 However, there is not a single study that has
evaluated the prevalence of AF in patients commencing
dialysis, or of its incidence in the course of the clinical
evolution of dialysis treatment.
The objective of this study was to analyze the prevalence of
AF in patients starting dialysis, to determine its incidence in
the course of dialysis in those not identified as having AF at
the start of dialysis, and to establish the influence of AF on
stroke and mortality.
RESULTS
There were 333 patients who commenced dialysis in our
center over the recruitment period. Of these, nine recovered
renal function, 14 were referred to us from another center,
25 had received a previous transplant, and 29 died early or
had changed their residence outside our catchment area.
The remaining 256 patients were included in this study. The
clinical characteristics and the echocardiographic data are
summarized in Table 1.
Prevalence of AF
Of the 256 patients, 31 (12.1%) were diagnosed as having AF
in one or other of its clinical manifestations. Of these,
19 (7.4%) had permanent AF and there had been an earlier
episode documented in 12 (4.7%). The patients with AF were
predominantly women, older age group, higher body mass
index, greater left ventricular hypertrophy, and greater
dimensions of the left atrium. The concentrations of
creatinine were lower and those of C-reactive protein were
higher in the patients with arrhythmia. Of the patients with
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arrhythmia, four of every five had annular or valvular
calcifications, and two of three embolisms suffered were by
patients presenting with AF.
Table 1 summarizes the differences between the patients in
whom AF had been identified at the start of the dialysis and
those who were in sinus rhythm.
In the multivariate analysis, greater age, greater left atrial
dimensions, and female gender were independently associated
with the presence of AF at the start of dialysis (Table 2).
Incidence of AF
During follow-up, 86 patients died, five had changed their
place of residence out of our clinical catchment area, and 28
received transplants. The mean follow-up in the overall group
was 24.22±14.6 months, which represents 516.69 patient-
years of follow-up. The mean follow-up of patients in whom
AF had not been documented at the start of dialysis (n¼ 225)
was 25.08±14.44 months, which represents a follow-up of
470 patient-years. Of these 225 patients, 28 (12.4%) had an
episode of AF documented in the follow-up. This represents
an incidence of 5.9 per 100 patient-years of follow-up.
The patients who had AF in follow-up (60.7% males) were
older, with a higher body mass index, higher pulse pressure,
had more ischemic stroke or transient ischemic attack (TIA),
and one in every four had presented with bundle branch
block. The echocardiographic analysis showed larger dimen-
sion of left ventricle, greater hypertrophy of the left ventricle,
a lower ejection fraction, and four of every five had valvular
calcifications. The hematological and biochemical parameters
showed that the patients who developed arrhythmia were
more anemic, and had lower concentrations of calcium and
Table 1 | Clinical characteristics and hematological, biochemical, and echographic parameters of the overall study group
All (n=256) SR (n=225) AF (n=31) Pa
Age (years) 65.0±15.9 63.5±16.1 76.7±7.3 0.001
Females (%) 110 (43) 89 (39.5) 21 (67.7) 0.003
Smokers (%) 68 (26.1) 63 (28) 5 (16) 0.161
BMI (kg/m2) 27.4±5.2 27.1±5.0 29.8±6.0 0.005
Pulse pressure (mm Hg) 55.9±21.3 55.1±21.3 61.9±20.7 0.095
Previous hypertension (%) 214 (83.6) 190 (84.4) 24 (77.4) 0.322
Diabetes on hypoglycemic treatment (%) 73 (28.5) 64 (28.4) 9 (29) 0.946
Hemodialysis treatment (%) 213 (83.2) 186 (82.7) 27 (87) 0.536
Documented previous ischemic stroke or TIA (%) 19 (7.4) 16 (7.1) 3 (9.7) 0.609
Documented previous coronary disease (%) 21 (8.2) 19 (8.4) 2 (6.4) 0.705
Documented previous peripheral embolism (%) 3 (1.2) 1 (0.4) 2 (6.4) 0.004
Bundle branch block (%) 25 (9.8) 21 (9.3) 3 (12.9) 0.530
Hemoglobin (g per 100 ml) 10.6±2.1 10.5±1.5 10.0±1.2 0.068
Platelets (n 103/ml) 237±87 241±897 216±678 0.139
Urea (mg per 100 ml) 143.7±51.3 142.8±50 150.8±60 0.416
Creatinine (mg per 100 ml) 6.7±2.3 6.8±2.3 5.6±2.1 0.007
Albumin (g per 100 ml) 3.55±0.54 3.58±0.54 3.38±0.48 0.060
Calcium (albumin corrected) (mg per 100 ml) 9.3±0.9 9.3±0.9 9.4±0.7 0.390
Phosphorus (mg per 100 ml) 5.1±1.7 5.2±1.7 4.6±1.4 0.097
Intact parathormone (pg/ml) 253±247 258±256 209±256 0.304
Ferritin (ng per 100 ml) 315±372 312±360 334±455 0.762
Transferrin (mg per 100 ml) 200±164 200±174 198±47 0.961
Glycosylated hemoglobin (%) 4.63±1.12 4.64±1.14 4.61±0.93 0.878
Homocysteine (mmol/l) 24.4±9.5 24.4±9.3 24.3±11.4 0.958
C-reactive protein (mg per 100 ml) 14.2±24.5 11.9±20.3 30.9±41.2 0.017
Cholesterol (mg per 100 ml) 159±38 160±38 152±35 0.256
Triglycerides (mg per 100 ml) 139±78 140±79 134±73 0.704
Left atrial dimension (mm) 41.3±7.6 40.5±7.3 47.5±6.8 0.000
Ejection fraction (%) 65.0±9.2 65.5±9.1 62.1±9.4 0.060
Ascending aorta dimension (mm) 32.7±3.9 32.8±3.9 32.1±4.2 0.395
LVI mass/body surface (g/m2) 165.4±52.7 162.0±5.4 191.0±56.1 0.006
E/A ratio mitral filling flow 0.89±0.42 0.89±0.43 0.80±0.33b 0.511
Presence of valvular calcifications (%) 128 (50) 103 (45.8) 25 (80.6) 0.000
AF, atrial fibrillation; BMI, body mass index; LVI, left ventricle; SR, sinus rhythm; TIA, transient ischemic attack.
aSR vs AF.
bPatients with non-permanent AF who were in SR at the time of the evaluation
Analysis of patients with AF vs SR at the start of dialysis. Student’s t-test or Mann–Whitney test for quantitative variables and Pearson’s w2-test for qualitative variables.
Table 2 | Factors independently associated with the presence
of atrial fibrillation at the start of the dialysis
Variable Odds ratio 95% CI P
Female gender 2.62 1.03–6.64 0.042
Left atrial dimension 1.13 1.06–1.22 0.001
Age 1.07 1.02–1.13 0.008
CI, confidence interval.
Multivariate logistic regression, including gender, age, body mass index, pulse
pressure, left ventricular mass/body surface, left atrial dimension, presence of
calcifications, left ventricular ejection fraction, hemoglobin, creatinine, albumin,
C-reactive protein, and phosphorus.
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albumin. Table 3 summarizes the differences between the
patients who presented with AF and those who maintained
sinus rhythm.
In the multivariate analyses, the variables, such as presence
at the start of dialysis of calcifications or bundle branch
block, a previous stroke or TIA, lower ejection fraction, a
higher pulse pressure, and lower level of hemoglobin, were
shown to be independent predictors of AF in the course of
the clinical evolution of dialysis (Table 4).
Analysis of mortality
Atrial fibrillation had a significant influence on mortality. A
total of 86 patients died during follow-up. Table 5 sum-
marizes the presence of arrhythmia, not only at the start of
dialysis but also in the clinical evolution, in patients who died
and those who were alive at the end of the study period.
The independent predictors of mortality were the presence
of AF irrespective of time of diagnosis, older age, previous
stroke or TIA, and a lower concentration of albumin
(Table 6).
The survival curves show a clear difference between the
patients who presented with AF and those in whom there had
not been any episode of arrhythmia detected, either in the
overall patient group or when dichotomized with respect to
age 465 years (Figure 1).
Analysis of ischemic stroke
There were seven patients who suffered an ischemic stroke
during follow-up. This represents a rate of 1.35 ischemic
strokes per 100 patient-years of follow-up. One of these
patients had been receiving anticoagulants with an INR
(international normalized ratio) within the range pro-
grammed (2–3) when the event occurred. Of the 59 patients
who had AF at any time during the study, 34 (57.6%) were
treated with oral anticoagulants.
Five of the seven patients (71.4%) who suffered an
ischemic stroke had been diagnosed as AF at some time in the
course of the dialysis. AF irrespective of the time of diagnosis
and AF in the course of the dialysis together with previous
ischemic stroke, higher number of platelets, and higher
hematocrit were related to the presence of ischemic stroke
(Table 7).
Table 3 | Differences between patients who developed AF over the course of the follow-up and those who maintained sinus
rhythm, including statistically significant variables
Variable SR (n=197) AF (n=28) P
Age (year) 61.9±16.4 74.5±8.7 0.001
BMI (kg/m2) 26.8±4.9 29.1±4.8 0.026
Pulse pressure (mm Hg) 53.3±20.2 67.3±24.6 0.001
LV/BS mass (g/m2) 158.9±51.1 184.5±48.2 0.017
LVEF (%) 65.9±9.1 62.3±8.9 0.059
LA dimension (mm) 40.1±7.1 43.6±8.4 0.021
Hemoglobin (g per 100 ml) 10.6±1.5 9.9±1.6 0.024
Calcium (albumin corrected) (mg per 100 ml) 9.3±0.9 8.8±0.8 0.009
Albumin (g per 100 ml) 3.6±0.5 3.4±0.5 0.047
Valvular calcifications (%) 80 (40.6) 23 (82.1) 0.001
Bundle branch block (%) 14 (7.1) 7 (25) 0.002
Previous ischemic stroke or transient ischemic attack (%) 11 (5.6) 5 (17.9) 0.018
AF, atrial fibrillation; BS, body surface; BMI, body mass index; LA, left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; SR, sinus rhythm.
Univariate analysis. Student’s t-test or Mann–Whitney test for quantitative variables and Pearson’s w2-test for qualitative variables.
Table 5 | Differences in the presence of arrhythmia in the
patients who died and those who survived over the long
term of follow-up
Dead (n=86) Alive (n=170) P
AF at the start of dialysis (n (%)) 18 (20.9) 13 (7.6) 0.002
AF in the course of dialysis (n (%)) 18 (20.9) 10 (5.9) 0.001
AF at any period (n (%)) 36 (41.9) 23 (13.5) 0.001
AF, atrial fibrillation.
Peason’s w2-test.
Table 4 | Factors independently associated with the presence
of atrial fibrillation over the clinical course of dialysis
Variable Odds ratio 95% CI P
Valvular calcifications 5.23 1.74–15.67 0.003
Bundle branch block at start of dialysis 5.92 2.22–15.77 0.000
Previous ischemic stroke or transient
ischemic attack
3.53 1.12–11.12 0.031
Left ventricle ejection fraction 0.05 0.91–0.99 0.021
Pulse pressure 1.02 1.00–1.03 0.018
Hemoglobin concentration 0.71 0.52–0.97 0.036
CI, confidence interval.
Cox’s regression analysis, including age, previous ischemic or transient ischemic
attack, calcifications, bundle branch block, body mass index, pulse pressure, left
ventricular mass/body surface, left atrial dimension, left ventricular ejection fraction,
hemoglobin, albumin-corrected calcium, and albumin.
Table 6 | Factors independently associated with mortality
Variable Odds ratio 95% CI P
Previous ischemic stroke or transient
ischemic attack
3.31 1.66–6.59 0.001
Age 1.05 1.02–1.07 0.001
Albumin 0.52 0.32–0.84 0.007
AF at any time 1.72 1.06–2.80 0.027
AF, atrial fibrillation; CI, confidence interval.
Cox’s regression analysis, including age, hemodialysis vs peritoneal dialysis, previous
ischemic stroke or transient ischemic attack, left ventricle ejection fraction, ventricle
mass/body surface, left atrial dimensions, calcifications, creatinine, bundle branch
block, albumin, AF at any time, and pulse pressure.
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In the multivariate analyses, AF irrespective of time of
diagnosis was the major independent predictor of ischemic
stroke presentation, and a higher risk was associated with
having had a previous stroke or TIA (Table 8).
The mean follow-up of the patients with AF irrespective of
time of diagnosis was 21.39±14.6 months. This represents a
follow-up of 105.16 patient-years and a rate of ischemic
stroke of 4.75 per 100 patient-years. The mean follow-up of
patients who maintained sinus rhythm was 25.06±14.5
months. This represents a follow-up of 411 patient-years and
a rate of ischemic stroke of 0.48 per 100 patient-years. As
such, the presence of AF implies a 9.8-fold increase in risk of
stroke.
DISCUSSION
This study showed a high prevalence and incidence of AF in
patients starting dialysis.
The data from this study cannot be compared with other
studies as the literature lacks such studies that analyze AF in
patients commencing dialysis. When we compare data of
prevalence from our population with the general population,
we see that AF is present in a higher proportion in the
patients who started dialysis.4,12,13
In interpreting the high percentage prevalence in our
study, we need to take into account that the patient
population had a mean age of 65 years, with an elevated
body mass index, almost all were hypertensive, almost
30% were diabetic, and 10% had bundle branch block.
Echographic parameters indicated that dilated left atrium,
and annular and/or valvular calcification were present in
half the number of patients. Only 3 of the 146 males had a left
ventricular mass o120 g/m2 and only 1 of the 110 females
had o100 g/m2. The ejection fraction was, nevertheless,
445% in 240 of the 256 patients (93.7%). Given that the
majority of these factors have been shown in the general
population to be associated with AF,4,12–15 this high
prevalence can be attributable to a confluence of factors
and, as such, complicates the evaluation of the influence of
renal insufficiency per se on the presence of AF.
The patients who presented with AF at the start of dialysis
were older and more obese. They had higher pulse pressure,
greater left ventricular hypertrophy, greater dimensions of left
atrium, and more calcification. All these factors had been
associated with AF.4,7,12–18 Although the association between
calcifications and chronic renal disease is well documen-
ted,19,20 as is the relationship between calcifications and
disorders of conduction,21,22,23 there has been only one
previous study that has described an association between
calcifications and AF.7 The relationship between female
gender and AF that we had observed is not concordant with
the findings in previous studies conducted in our own
institution; we had either not observed significant differences
between the genders or, indeed, had observed a preponder-
ance of males with AF.8,10
The incidence of new cases of AF is not only higher than
that observed in the general population,12 but also higher than
that described for the population on dialysis. Although there
have not been any studies such as ours evaluating the
incidence of arrhythmia in patients commencing dialysis, we
can make comparisons between our study and those studies
that had evaluated the incidence of AF in patients already
included in dialysis programs. Our previous study showed an
annual incidence of 3.1% in a patient population with a mean
time on dialysis of 43 months.10 The study by Genovesi et al.,11
with a median time on dialysis of 45.2 months, showed an
annual incidence of 4.1%. This was 1% in the study by Ansari
et al.24 These differences can be attributed to several reasons.
First, we need to highlight that in our study, the patients had
been followed-up prospectively, with a strict follow-up that
would detect any episode of AF that may have occurred.
Another important aspect is the age of the population. In our
previous study, the mean age of the patients in sinus rhythm
was 57 years of age but which, in this study, was 65 years.
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Figure 1 | Survival curves of dialysis patients with AF and
those who maintained sinus rhythm (AF, atrial fibrillation;
SR, sinus rhythm).
Table 7 | Differences between patients with and without





Age (years) 74.7±14.9 64.8±15.9 0.040
Platelets (n 103/ml) 309±130 235±85 0.029
Hematocrit (%) 35.1±6.5 31.3±4.6 0.036
Previous ischemic stroke or TIA
(n (%))
2 (28.6) 17 (6.8) 0.030
AF in the course of dialysis (n (%)) 3 (42.9) 25 (10) 0.006
AF at any time (n (%)) 5 (71.4) 54 (21.7) 0.002
AF, atrial fibrillation; TIA, transient ischemic attack.
Univariate analysis. Student’s t-test or Mann–Whitney test for quantitative variables
and Pearson’s w2-test for qualitative variables.
Table 8 | Factors independently associated with the presence
of ischemic stroke in the course of the dialysis period
Odds ratio 95% CI P
Previous stroke or transient ischemic attack 6.98 1.24–39 0.027
AF at any time 17.3 1.99–150 0.010
AF, atrial fibrillation; CI, confidence interval.
Cox’s regression analysis, including age, previous ischemic stroke or transient
ischemic attack, AF at any time, hematocrit, platelets, and diabetes.
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Some aspects need to be highlighted in relation to the
differences in the clinical profile of the patients who
developed arrhythmia in the course of the dialysis compared
with those who remained in sinus rhythm. AF has been
associated with a greater left atrial size, including in patients
on dialysis,9 but there has always been doubt as to whether
this dilation is the cause or the consequence of the AF.25
There are studies in the general population that have
reported atrial dilation as predisposing to the development
of arrhythmia,26 but our study is novel in that it describes
this relationship in patients on dialysis.
That ischemic stroke or TIA is present before commencing
dialysis and can be a predictive factor in the development of
AF is, in our opinion, of considerable clinical interest. It is
evident that the AF can only be diagnosed when it is
documented, but this does not exclude the possibility that
other non-documented episodes may have occurred and
which could result in the cerebral ischemia. Our finding can
suggest that the patients who had suffered an ischemic stroke
or TIA already had the arrhythmia, but that it had not been
detected. This implies that the patients who began dialysis
with a previous stroke should be followed-up carefully so
that those episodes of AF that are brief and self-limiting,
but nonetheless thrombogenic, do not pass unnoticed. New
equipment of continuous electrographic monitoring27 can
have an important role as a diagnostic tool in this group of
patients.
Valvular calcifications constitute a factor that is indepen-
dently associated with clinical evolution of AF. The most
notable aspect in our analysis, nevertheless, was that the most
important independent predictive factor in the development
of arrhythmia that we had observed was the presence of
bundle branch block at the commencement of dialysis. In a
recent study carried out in our center, we noted that branch
block is a very prevalent finding in the population on
dialysis.23 Nevertheless, there are no studies, in patient
population on dialysis, which relate disturbances in intra-
ventricular conduction with the presence of AF. In this study,
its presence at the start of dialysis increases the probability of
developing the arrhythmia over the clinical course of the
dialysis by sixfold.
The presence of AF has had an evident influence on
survival in our patients. In two studies previously conducted
in our own institution, AF represented a 2.1-fold increase in
mortality risk28 and, in the other study, the mortality rates in
the first and second year of follow-up were 38 and 53%,
respectively, in the AF group and 14 and 31%, respectively, in
the sinus rhythm group.10 In the Genovesi et al. study11 the
incremental all-mortality risk that implied the presence of AF
was quantified as being 1.65-fold and, from cardiovascular
cause, it was 2.15-fold. The influence of AF on the patients
who commenced dialysis is not very different from that
pertaining to the general population,29–31 although there is an
increase in the mortality risk that is already very elevated.
Atrial fibrillation has a clear importance in the clinical
evolution of ischemic cerebrovascular accident. In our study,
the presence of AF increased the probability of developing an
ischemic stroke by 9.8-fold. The Framingham study places
this at fivefold in the general population.32 The results of this
study are not in agreement with the scarce information
available in the literature.11,33 The recent study by Genovesi
et al.11 did not observe an increased risk associated with the
presence of AF. We believe that one of the reasons could be
the different methodologies employed. For example, Geno-
vesi et al. considered presenting with a stroke as that
occurring within the overall time period of the 3 years of
their study. However, many patients had died during this
period. If we take into account that the patients with AF had
a mortality rate significantly higher than the patients in sinus
rhythm, and that the mortality in the first years in patients
with AF was 31%,9 then the time over which the patients
with AF had been exposed to the risk of stroke was lower. All
of our published studies had analyzed the risk of presenting
with an ischemic stroke only during the period in which the
patients were followed-up and, in all of them, the AF
increased the risk of the event. The increase in risk in this
study (9.8-fold) is higher than that encountered in our other
studies in which the patients with AF were observed to have a
4.6-fold31 or 5.2-fold10 increase in the probability of suffering
a thromboembolic event. Our opinion, supported by the
results of this and other previous studies,8,10,31 is that AF
constitutes an important thromboembolic risk factor not
only in the general population, but in patients with end-stage
renal disease as well. This implies that antithrombotic
therapy needs to be implemented if the risk of these
complications is to be reduced. The question that remains
to be answered is whether the patients with AF on dialysis
need to be treated with oral anticoagulants. The studies that
had evaluated the benefit of anticoagulant therapy for
patients with AF had excluded patients with end-stage renal
disease and, as such, the risk–benefit relationship of the
therapy in this population has not been evaluated. Classically,
chronic renal insufficiency with anticoagulant therapy has
been associated with a high risk of bleeding. However, this
risk has not been established within the context of current
conditions of efficacy and quality of dialysis. In a retro-
spective study conducted in our center,34 the use of
anticoagulant treatment resulted in a 2.3-fold increase in
the risk of bleeding. However, this increase was not related to
fatal intracranial hemorrhage or associated sequelae. The
only recent study that analyzed the repercussion of antic-
oagulation on the clinical evolution of the patients on dialysis
was carried out by Abbot et al.,35 and their results indicated a
clear benefit. Alternative therapeutic options can be the use
of antiplatelet agents, but these are not exempt from
hemorrhagic risk either.36 Opinions vary, and there are some
who consider that the current recommendations for the
general population are not applicable to patients on dialysis,
that is, that the patients with AF on dialysis are not to be
treated with anticoagulants.37,38 Our opinion is that, in
patients with chronic renal insufficiency being treated with
dialysis, the increase in the risk of bleeding does not
328 Kidney International (2009) 76, 324–330
o r i g i n a l a r t i c l e E Vazquez et al.: Atrial fibrillation in incident dialysis patients
constitute an a priori contraindication to oral anticoagulant
treatment. However, earlier evaluation of the embolic and
hemorrhagic risk is necessary in each patient. This recom-
mendation is consistent with the data from two recent
analyses6,39 which indicated that treatment with warfarin
should be considered in the prevention of thromboembolism
in patients with AF undergoing dialysis.
In addition to the inherent limitations of a single-center
study, we cannot discard the possibility of brief and self-
limited asymptomatic episodes passing unnoticed and, as
such, the frequency of AF would be higher. On the other
hand, in the group of patients starting dialysis with non-
permanent AF, the different clinical patterns of presentation
had not been analyzed as it had not been possible to deter-
mine the number of episodes in all the cases and whether
sinus rhythm had spontaneously recovered. Hence, in the
echocardiographic assessments, we did not take into account
the time of the measurements in relation to the dialysis
sessions and, as such, the assessments were not carried out in
all the patients under similar loading conditions.
PATIENTS AND METHODS
All procedures were conducted within the guidelines of Good
Clinical Practice, and all patients provided informed consent
to participate in the study.
The design of the study was prospective and observational.
To establish the prevalence of AF in the patients who
commence dialysis, we evaluated all those who began dialysis
(hemodialysis or peritoneal dialysis) between 1 November
2003 and 15 September 2007 in our hospital and its satellite
health-care centers.
Excluded from the study were those who had commenced
treatment in centers not associated with our institution, had
previously received a kidney transplant, those who had
recovered renal sufficiency and did not need dialysis, and
those who, within the first few sessions of dialysis, had died
or changed residence to outside our clinical catchment area.
Atrial fibrillation was considered when the arrhythmia
was permanent or had been documented in any of our
electrocardiographic databases. Follow-up of the patients
continued up to 30 May 2008 or until death, renal transplant,
or change of residence beyond our remit of dialysis provision
had taken place. The patients were treated according to the
attending physician with no specific recommendation with
respect to the treatment of the arrhythmia or antithrombotic
medications.
An electrocardiogram was scheduled to be carried out
annually and, as well, at any time that the patient had any
symptoms that suggested the presence of arrhythmia, or if
alterations in the rhythm were detected in the course of the
dialysis session. The incidence of AF was established in those
patients who, at the time of inclusion into the study, were in
sinus rhythm and in whom the presence of arrhythmia had
not been noted. Arrhythmia was considered when documen-
ted, irrespective of the number of episodes or of the clinical
pattern of presentation.
All the patients had an evaluation within the first month
of placement on dialysis. This included cardiological clinical
history, electrocardiogram, the measurement of hematologi-
cal and biochemical parameters, and a color Doppler
echocardiogram. The factors associated with, or predisposing
to, AF were measured and so was the influence of the
arrhythmia on ischemic stroke and mortality. The variables
measured included age, gender, smoking habit, body mass
index, pulse pressure, diabetes, arterial hypertension, bundle
branch block, presence of previously documented coronary
disease (myocardial infarction or coronary lesions 470% in
the coronary angiography), presence of ischemic stroke, TIA,
or previous peripheral embolism. Hematological parameters
measured included hemoglobin, hematocrit, and platelets.
Biochemical parameters measured included urea, creatinine,
albumin, cholesterol, triglycerides, CRP, intact parathor-
mone, calcium, phosphorus, ferritin, transferrin, glycosylated
hemoglobin, and homocysteine. Color Doppler echocardio-
graphy was used to measure the following parameters: left
atrial size, left ventricular dimensions, left ventricular mass,
left ventricular ejection fraction, ascending aorta dimension,
presence of annular and/or valvular calcifications, and E/A
ratio in mitral filling flow. The presence of AF in the course of
dialysis was noted in relation to whether the patients were on
hemodialysis or peritoneal dialysis. Patients were recorded as
having hypertension or diabetes if, at the time of inclusion
into the study, they were receiving treatment for the control
of these diseases.
Statistical analyses
The Student’s t-test or the non-parametric Mann–Whitney
test was used in the descriptive analysis of the data.
Comparison of qualitative variables was carried out with
Pearson’s w2 test. Univariate and multivariate analyses were
carried out on all measured variables. The objective
prognostic variable of this study was the occurrence of the
event or diagnosis of AF in the follow-up. The study was
based on an analysis of the predictors at the start of treatment
using Cox’s regression of proportional risk. The variables
included were those that, in the overall patient group, were
statistically significant in univariate analysis, as well as those
that were not statistically significant, but were of clinical
relevance. The same assessment was applied with respect to
death or presence of ischemic stroke in the course of dialysis.
The best predictive model was obtained using the procedure
of progressive conditional incorporation. The odds ratio and
the 95% confidence interval were calculated. Survival analysis
was carried out comparing Kaplan–Meier curves using the
log-rank test. In all tests, a probability of Po0.05 was
considered as statistically significant.
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